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Abstract
Introduction: HIV retesting during late pregnancy and breastfeeding can help detect new maternal infections and prevent
mother-to-child HIV transmission (MTCT), but the optimal timing and cost-effectiveness of maternal retesting remain uncertain.
Methods: We constructed deterministic models to assess the health and economic impact of maternal HIV retesting on a
hypothetical population of pregnant women, following initial testing in pregnancy, on MTCT in four countries: South Africa and
Kenya (high/intermediate HIV prevalence), and Colombia and Ukraine (low HIV prevalence). We evaluated six scenarios with
varying retesting frequencies from late in antenatal care (ANC) through nine months postpartum. We compared strategies
using incremental cost-effectiveness ratios (ICERs) over a 20-year time horizon using country-specific thresholds.
Results: We found maternal retesting once in late ANC with catch-up testing through six weeks postpartum was cost-effec-
tive in Kenya (ICER = $166 per DALY averted) and South Africa (ICER=$289 per DALY averted). This strategy prevented
19% (Kenya) and 12% (South Africa) of infant HIV infections. Adding one or two additional retests postpartum provided smal-
ler benefits (1 to 2 percentage point increase in infections averted versus one retest). Adding three retests during the post-
partum period averted additional infections (1 to 3 percentage point increase in infections averted versus one retest) but
ICERs ($7639 and in Kenya and $11 985 in South Africa) greatly exceeded the cost-effectiveness thresholds. In Colombia and
Ukraine, all retesting strategies exceeded the cost-effectiveness threshold and prevented few infant infections (up to 31 and 5
infections, respectively).
Conclusions: In high HIV burden settings with MTCT rates similar to those seen in Kenya and South Africa, HIV retesting
once in late ANC, with subsequent intervention, is the most cost-effective strategy for preventing infant HIV infections. In
these settings, two HIV retests postpartum marginally reduced MTCT and were less costly than adding three retests. Retest-
ing in low-burden settings with MTCT rates similar to Colombia and Ukraine was not cost-effective at any time point due to
very low HIV prevalence and limited breastfeeding.
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1 | INTRODUCTION
Despite successful scale-up of prevention of mother-to-child
HIV transmission (PMTCT) programmes, an estimated
160 000 children worldwide became infected with HIV in
2018, with approximately 30% of these infections attributable
to incident maternal infections occurring after the first
antenatal care (ANC) visit [1-4]. Compared to established
infection, incident HIV infections acquired during pregnancy
or postpartum increase the risk of mother-to-child HIV trans-
mission (MTCT) nearly 10-fold, due to both high viral load
and the missed opportunity to detect these infections (and
implement interventions to prevent MTCT) if initial testing
occurs prior to transmission or seroconversion [5]. Identifying
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and treating maternal HIV infections is vital to achieving the
UNAIDS 95-95-95 fast-track targets for achieving low HIV
incidence by 2030 [6].
Universal HIV testing for pregnant women has been found
to be highly cost-effective, even in very low HIV prevalence
settings [7], and retesting during pregnancy and postpartum is
a promising approach to reduce MTCT risk. The World Health
Organization (WHO) has recommended retesting in the third
trimester or during labour/delivery in high HIV prevalence
settings since 2006, and retesting during breastfeeding since
2015 [8,9]. Despite the promise of maternal HIV retesting,
health and economic impacts and optimal timing and fre-
quency are not well-characterized [7,10]. Modelling analyses
in Uganda, South Africa and India have found retesting in late
pregnancy, at delivery, or very early in the postpartum period
to be cost-effective [11-13]. However, recent scale-up of ART
coverage and HIV prevention interventions limit the relevance
of these analyses, and in light of evidence that women in high
burden settings have high HIV risk throughout the postpar-
tum period [14,15], postpartum retesting warrants investiga-
tion.
The HIV funding gap is projected to increase to US$7.2 bil-
lion below that needed to achieve 2030 fast-track targets
[16]. As countries strive to achieve the elimination of MTCT
(EMTCT), policymakers must allocate limited resources effi-
ciently. To provide guidance to countries deciding whether to
implement maternal retesting, and if so the optimal frequency
and time(s) to retest, we assessed the cost-effectiveness of
various strategies of HIV retesting during pregnancy, labour/
delivery and postpartum in four countries representing a
range of national HIV prevalence.
2 | METHODS
2.1 | Model structure and retesting strategies
We constructed a deterministic state-transition model using
Excel (Microsoft Corporation, Redmond, WA, USA) to reflect
HIV disease progression, HIV testing and treatment during
pregnancy and postpartum (54 total states: 6 maternal HIV
stages stratified on 9 antenatal and postpartum periods)
(Appendices S1 and S2). We chose to model four countries
(South Africa, Kenya, Colombia and Ukraine) with varying
geography and HIV prevalence and adequate data availability.
Countries were classified based on WHO criteria as having
high (>15%, South Africa), intermediate (5% to 15%, Kenya)
and low national HIV prevalence (<5%, Colombia and Ukraine)
[7]. We modelled the annual number of pregnant women in
each country (or number of births as a proxy) and used
weekly time steps from the start of pregnancy to 12 months
postpartum. Infant disability-adjusted life years (DALYs) and
treatment costs were estimated over a 20-year time horizon.
We did not model infants explicitly; all cost and health events
occurring after infant infection were estimated from model
outputs. We evaluated six retesting scenarios varying the
number and timing of retests (Table 1). We selected retest
timing based on routine maternal and child health (MCH) vis-
its/immunization schedules and country policies [10]. Current
guidelines for retesting are as follows: South Africa – each
ANC visit, labour and delivery and every three months while
breastfeeding [17]; Kenya – third trimester, labour and
delivery, six weeks and six months postpartum [18]; Ukraine –
during pregnancy and labour and delivery only if high risk or
unknown status [19]; Colombia – second and third trimester
and labour and delivery [20]. We defined “late ANC” based on
each country’s ANC visit schedule, median gestational age at
ANC initiation and recommended HIV retesting interval. Late
ANC corresponds to a gestational age in the third trimester
in Kenya and South Africa and late second trimester in
Colombia and Ukraine (Table 2a).
2.2 | Model assumptions and parameterization
Model parameters (Table 2a; Appendix S3) were derived from
published literature (through April 2020), expert opinion, or
assumptions if data were not available. As our model simulates
a hypothetical population not corresponding to a specific year,
for all parameters we used the most up-to-date value avail-
able. HIV testing in our model requires visit attendance, tests
in stock, test acceptance and receipt of results. In the base
case scenario, HIV testing is offered only once at the first
ANC, which is assumed to occur at a country-specific gesta-
tional age. To reflect a setting in which retesting at delivery or
six weeks postpartum would only occur if women had not
retested previously, we modelled catch-up retesting at deliv-
ery to be conditional on the probability of not retesting at late
pregnancy, and retesting at six weeks postpartum to be condi-
tional on the probability of not retesting in late ANC or deliv-
ery.
We assumed no retesting between visits, no viral suppres-
sion during recent (acute) infection, no repeat or multiple
pregnancies and no foetal losses. We assumed all women diag-
nosed HIV-positive were ART eligible [21] and based ART ini-
tiation and viral suppression rates on country-specific
estimates. We assumed a constant weekly risk of ART discon-
tinuation resulting in 74% retention by one year postpartum
[22]. MTCT depended on pregnancy/postpartum period;
maternal disease stage, use of ART and viral load suppression;
infant use of antiretroviral prophylaxis (ARVs); and breastfeed-
ing practices (Appendix S3). Infant HIV testing was only
reflected in the probability an infected infant received ART,
Table 1. Maternal HIV retesting scenarios
Scenario
Late ANC with catch-up
testing at delivery and










6 U U U
7 U U U U
Cells containing a U denote a visit where retesting is offered. ANC,
antenatal care visit. Catch-up testing refers to testing at delivery for
those who did not test in late ANC, and testing at six weeks postpar-
tum for those who did not test at late ANC or delivery.
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Table 2a. Model parameters
Parameter Kenya South Africa Colombia Ukraine
Population of pregnant women 1 631 479 [41] 1 100 699 [42] 346 409b 363 946 [19]
HIV risk
HIV prevalence among pregnant women 6.1% [43] 31% [44] 0.4% [45] 0.7% [46]
Maternal HIV incidence rate (per person-
week)
Prior to first ANC during pregnancy 0.000331 [47] 0.000227 [15] 0.00001 0.000002 [48]
Between first ANC and delivery 0.000331 [47] 0.000739 [15] 0.00002a 0.000004 [48]
Delivery to 6 weeks postpartum 0a 0a 0a 0a
6 weeks to 12 months postpartum 0.000269 [47] 0.0009 [15] 0.000023a 0.000003 [48]
Duration of acute maternal HIV infection
(weeks)
9a 9a 9a 9a
HIV testing and prevention
Test kit stock out 5%a 5%a 0%a 0%a
Test acceptance 84% [49] 98% [50] 89%b 97% [19]
Receive test results 98% [51] 98% [52] 100%a 100%a
HIV test sensitivity in early infection 67%a 67%a 67%a 67%a
HIV test sensitivity in chronic infection 100% [53] 100% [53] 100% [53] 100% [53]
HIV test specificity 98.9% [53] 98.9% [53] 98.9% [53] 98.9%[53]
MTCT rate per week, acute maternal
infection
0.005 to 0.029 [54-58] 0.005 to 0.029 [54-58] 0.005 to 0.029 [54-58] 0.005 to 0.029
[54-58]
MTCT rate per week, chronic maternal
infection
0.0005 to 0.023 [54-58] 0.0005 to 0.023 [54-58] 0.0005 to 0.023 [54-58] 0.0005 to 0.023
[54-58]
Maternal PrEP use 0%a 0%a 0%a 0%a
Health care visits
Attend first ANC 96% [59] 94% [52] 97%b 99% [18]
Attend late ANC 93% [59] 78% [52] 88%b 90%a
Facility delivery 62% [59] 96% [52] 99%b 99% [60]
Attend postnatal MCH visits
6 weeks 96% [59] 90%b 92% [61] 99%a
14 weeks 88% [59] 73%b 87% [61] 93%a
6 months 87% [59] 86%b 90% [61] 96%a
9 months 85% [59] 62%b 89% [61] 95%a
First ANC (gestational age in weeks) 22 [23] 18b 15b 10a
Late ANC (gestational age in weeks) 33a 36a 24a 28a
Delivery (gestational age in weeks) 39a 39a 39a 39a
Early postpartum (weeks) 6a 6a 6a 6a
Mid postpartum (weeks) 26a 26 26a 26a
Antiretroviral coverage
Maternal ART use 91% [4] 87% [4] 88% [62] 95% [46]
Virally suppressedc 88% [63] 72% [64] 88% [63] 88% [63]
Weekly risk of ART dropout 0.33% [22] 0.33% [22] 0.33% [22] 0.33% [22]
HIV-exposed infants receiving ARVs 94% [23] 99%b 96%b 98%a
HIV-infected infants receiving ARTd 61% [43] 63% [78] 57.9% [62] 95% [46]
Breastfeeding practices among HIV infected women
Not breastfeeding in early postpartum (0
to 6 weeks)
2.5%b 34% [66] 95% [62] 95%a
Not breastfeeding in mid postpartum
(6 weeks to 6 months)
21%a 45% [66] 98% [62] 99%a
Not breastfeeding in late postpartum (6 to
12 months)
33%b 63% [66] 98% [62] 99%a
(Continued)
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taken as the product of the probability of testing and treat-
ment uptake. We assumed no pre-exposure prophylaxis (PrEP)
use in the main analyses. The model was validated against
estimated MTCT rates from each country [18,23-25]
(Appendix S4).
2.3 | Health outcomes
Modelled health outcomes included infant HIV infections,
deaths and DALYs. In addition to percent of total infant infec-
tions averted by each scenario, we calculated the percent of
maximum possible infant infections averted relative to no
retesting by excluding infant infections from women diagnosed
with HIV prior to pregnancy, as these women would neither
be eligible for nor benefit from additional HIV testing.
2.4 | Costs and cost-effectiveness
We estimated costs from a healthcare system perspective,
including costs for maternal retesting, maternal ART, infant
ARV prophylaxis and infant ART (Table 2b, Appendix S2).
Costs and resource utilization were obtained from the pub-
lished literature, a time-motion study in Kenya (Appendix S5),
in-country experts, or assumptions (Table 2b, Appendix S2).
Unit costs were applied to testing and treatment/prophylaxis
as women transitioned though model states. Costs were
adjusted to 2017 USD [26].
Weekly maternal ART costs were applied to women receiv-
ing ART and modelled through 12 months postpartum. We
modelled PrEP in scenario implementation analyses, with
women testing HIV-negative being eligible for PrEP and incur-
ring PrEP-related costs. Costs of infant prophylaxis were
applied as a one-time cost to women diagnosed by delivery.
Weekly ART costs were applied to HIV-infected infants
throughout the 20-year time horizon. Both costs and DALYs
were discounted at 3% annually [27].
We converted infant infections and deaths into DALYs [28].
We estimated DALYs through 20 years of life using country-
specific WHO life tables and age- and HIV status-specific mor-
tality estimates from published literature (Appendices S2 and
S3) [29,30]. We choose a time horizon of 20 years for compa-
rability with other HIV cost-effectiveness analyses. We calcu-
lated the incremental cost-effectiveness ratio (ICER) as the
change in costs divided by the change in health outcomes
compared with the next best alternative. Strategies that were
more costly and less effective (“strongly dominated”) or less
costly and less cost-effective (“weakly dominated”) than an
alternative strategy were considered inefficient [31] and elimi-
nated from the calculations. We used country-specific cost-ef-
fectiveness thresholds based on the estimated opportunity
cost of health investment foregone. We adopted thresholds of
$500 (Kenya) [32,33]; $750 (South Africa), derived in [34] as
Table 2a. (Continued)
Parameter Kenya South Africa Colombia Ukraine
Maternal mortality rate (per person-week)
During pregnancy 0.0001 [29] 0.0001 [29] 0.00002 [29] 0.00002 [29]
Delivery through 6 weeks postpartum 0.0006 [68] 0.0002 [68] 0.0001 [68] 0.00003 [68]
6 weeks to 12 months postpartum 0.0001 [29] 0.0001 [29] 0.00002 [29] 0.00002 [29]
Neonatal/infant mortality (per person-week) and survival probabilities
Neonatal mortality, birth-6 weeks 0.0049 [69] 0.0029 [69] 0.0018 [69] 0.0011 [69]
Infant mortality, >6 weeks to 12 months 0.00031 [69] 0.00025 [69] 0.00009 [69] 0.00006 [69]
Survival to 1 year, HIV 96% [29] 97% [29] 99% [29] 99% [29]
Survival to 1 year, HIV + on ART 96% [29] 97% [29] 99% [29] 99% [29]
Survival to 1 year, HIV + not on ART 65% [30] 65% [30] 65% [30] 65% [30]
ANC, antenatal care; ARV, antiretroviral prophylaxis; ART, antiretroviral therapy; MCH, maternal and child health; MTCT, mother-to-child trans-






among women on ART;
d







2.64a 7.72a,b 6.68a,b 3.99a,b
True-positive screening
tests per woman†
3.68a 11.39a,b 8.53a,b 4.18a,b
False-positive screening
tests per woman†
26.39a 34.17a,b 74.83a,b 19.80a,b
Maternal ART, per
week
4.86 [71] 4.79 [72] 18.89b 32.84 [73]
Infant ARV prophylaxis
(total cost)
2.32 [74] 3.82 [74] 52.10b 4.00b
Maternal PrEP, per
week
6.19 [75] 6.19 [75] 18.89b 19.38 [76]
Infant ART, per week
(birth to 2 weeks)
6.73 [77] 5.46 [74] 18.89b,c 32.84c
Infant ART per week
(2 weeks to 1 year)
6.73 [77] 5.46 [74] 18.89c 32.84c
All costs provided in 2017 USD and include labour and supplies. ART,
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in Phillips et al. [35]; $1000 (Ukraine) [36] and $3000 (Colom-
bia) [37] per DALY averted. We followed the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) in
preparing this manuscript [38].
2.5 | Scenario implementation and uncertainty
analyses
We estimated the sensitivity of Scenario 2 results in Kenya
and South Africa to uncertainty in key parameters by mod-
elling 20% relative increases and decreases (bounded by 0
and 1 for probabilities). We also evaluated the sensitivity of
model Scenarios 2 and 3 in each country to reductions in
maternal HIV incidence and prevalence, and introduction of
PrEP. We modelled PrEP use among 5%, 10% and 15% of all
HIV-negative women. We additionally modelled a combination
scenario of 15% PrEP use and 20% reduction in both mater-
nal HIV prevalence and incidence. Last, to assess whether the
benefits of retesting would change with an optimized HIV care
cascade, we estimated the percentage of infections averted
with retesting assuming 100% MCH attendance, test cover-
age, treatment initiation, retention, viral suppression and infant
ARV prophylaxis coverage (Appendix S6).
2.6 | Ethical statement
This research involved no identifiable data, and as such does
not constitute human subjects research.
3 | RESULTS
Model results are presented in Table 3 and Figure 1. In
Kenya and South Africa, HIV retesting among women of HIV-
negative or unknown status in late ANC, with catch-up testing
through six weeks postpartum for women not tested in late
ANC, is projected to prevent 19% and 12% of infant infec-
tions respectively. In both countries, ICERs associated with
this retesting strategy ($166 and $289 per DALY averted for
Kenya and South Africa respectively) fell below the cost-effec-
tiveness thresholds. In these countries, adding one or two
additional HIV retests postpartum provided only small incre-
mental benefits (1 to 3 percentage point increase in HIV
infections averted), and provision of one additional test at
14 weeks postpartum-dominated scenarios in which this test
was offered at six, nine, or both six and nine months postpar-
tum. HIV retesting in late ANC and every three months post-
partum was the most effective and most costly strategy,
exceeding the cost-effectiveness thresholds with ICERs of
$7639 per DALY averted in Kenya and $11 985 in South
Africa.
In Colombia, HIV retesting in late ANC with early postpar-
tum catch-up averted a similar proportion of HIV infections
(17%) as in Kenya and South Africa (19% and 12% respec-
tively), whereas this strategy averted fewer infections in
Ukraine (6%). However, due to the low HIV burden, the abso-
lute number of infections prevented was small in both coun-
tries (23 in Colombia and 4 in Ukraine). Adding additional HIV
retests followed a similar pattern to that of Kenya and South
Africa, providing marginal incremental benefits but with sub-
stantially higher costs. All HIV retesting scenarios in Colombia
and Ukraine were either dominated or exceeded the cost-ef-
fectiveness thresholds.
When restricting our results to women eligible for retesting
(those without known HIV infection at the start of pregnancy),
retesting in late ANC with early postpartum catch-up testing
averted 23% of infections in Kenya, 19% in South Africa, 20%
in Colombia and 24% in Ukraine. Consistent with our main
results, additional postpartum retests increased the percent of
maximum potential infections averted but with diminishing
returns.
3.1 | Scenario implementation and uncertainty
analyses
In uncertainty analyses, ICERs for HIV retesting in late ANC
with catch-up retesting through six weeks postpartum ranged
from $102 to $272/DALY averted in Kenya and from $156 to
$799 for South Africa (Figure 2). Changes in HIV test cover-
age, followed by infant ART cost, had the largest impact on
ICERs. In all countries, increases in PrEP use, decreases in
HIV incidence, and decreases in HIV prevalence resulted in
larger ICERs (Figure 3a-h) and fewer HIV infections averted
(Figure S1). All scenario analyses of retesting in late ANC in
Kenya and South Africa remained below the cost-effectiveness
thresholds. Maternal retesting impact on MTCT was lowest
when maternal incidence was reduced by 30%. Under an opti-
mized care cascade, retesting in late ANC (with catch-up test-
ing) and every three months postpartum averted 19% to 22%
of infections in South Africa and Kenya (Appendix S6).
4 | DISCUSSION
We evaluated the health and economic impact of maternal
HIV retesting at varying frequencies and intervals in four
countries representing a range of HIV prevalence. In the inter-
mediate- and high-prevalence settings of Kenya and South
Africa, our results indicate retesting in late ANC with catch-up
testing through early postpartum should be prioritized to cap-
ture as many maternal seroconversions occurring during preg-
nancy as possible. In such settings, retesting later in the
postpartum period can capture maternal infections acquired
after delivery but should only be considered in addition to
retesting earlier in pregnancy/postpartum. As retesting in late
ANC with catch-up testing and quarterly postpartum (Scenario
7) most closely aligns with current South African guidelines
[17], reducing the frequency of postpartum retesting may be
effective in optimizing maternal HIV retesting with limited
resources. In the low prevalence settings of Columbia and
Ukraine, all HIV retesting strategies were dominated or
greatly exceeded cost-effectiveness thresholds. Retesting in
late ANC with catch-up testing prevented the largest number
of infant HIV infections, but the absolute number was small
(<25 infections annually).
Our model results also highlight limits on retesting as a
strategy for EMTCT. While one-third of infant infections are
attributable to incident maternal infections [4], even with fre-
quent testing throughout pregnancy and postpartum the pro-
portion of infant infections averted due to retesting was only
27% in Kenya and 21% in South Africa after excluding MTCT
attributed to women diagnosed with HIV prior to pregnancy.
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Table 3. Infant HIV infections, deaths, disability-adjusted life years (DALYs) averted and cost-effectiveness of maternal HIV retest-



















1. No retesting 13 484 – – 61 651 $60 887 865 – 1 405 727 – –
2. Late ANCa,b 10 911 2573 19% 61 226 $63 295 344 $2 407 479 1 391 202 14 525 $166
5. Late ANC + 9 months 10 785 2699 20% 61 205 $66 901 930 – 1 390 493 – Dom
3. Late ANC + 14 weeks 10 656 2828 21% 61 184 $67 067 821 $3 772 477 1 389 764 1438 $2,623
4. Late ANC + 6 months 10 766 2717 20% 61 202 $67 253 849 – 1 390 387 – Dom
6. Late ANC + 6 months
+ 9 months
10 690 2793 21% 61 190 $70 505 634 – 1 389 957 – Dom
7. Late ANC + every
3 monthsc
10 502 2982 22% 61 158 $73 717 459 $6 649 639 1 388 893 871 $7639
SOUTH AFRICA
1. No retesting 27 038 – – 41 077 $144 227 239 – 906 680 – –
2. Late ANCa,b 23 838 3200 12% 40 564 $149 363 142 $5 135 903 888 889 17 792 $289
5. Late ANC + 9 months 23 747 3290 12% 40 550 $153 742 500 –– 888 387 – Dom
3. Late ANC + 14 weeks 23 616 3421 13% 40 529 $154 454 205 $5 091 063 887 657 1232 $4134
4. Late ANC + 6 months 23 703 3334 12% 40 543 $155 719 914 – 888 141 – Dom
6. Late ANC + 6 months
+ 9 months
23 650 3387 13% 40 534 $159 530 970 – 887 847 – Dom
7. Late ANC + every
3 monthsc
23 475 3562 13% 40 506 $163 855 053 $9 400 848 886 873 784 $11 985
COLOMBIA
1. No retesting 138 – – 4530 $4 658 472 – 89 810 – -
2. Late ANCa,b 115 23 17% 4525 $7 228 725 $2 570 253 89 648 162 $15 859
3. Late ANC + 14 weeks 111 28 20% 4524 $9 284 324 $2 055 599 89 615 34 $61 080
5. Late ANC + 9 months 112 26 19% 4524 $9 324 935 – 89 626 – Dom
4. Late ANC + 6 months 113 26 19% 4524 $9 373 546 – 89 629 – Dom
6. Late ANC + 6 months
+ 9 months
111 27 20% 4524 $11 433 846 – 89 616 – Dom
7. Late ANC + every
3 monthsc
107 31 23% 4523 $13 440 069 $4 155 745 89 590 24 $170 418
UKRAINE
1. No retesting 71 – – 3101 $8 470 318 – 57 636 – –
2. Late ANCa,b 67 4 6% 3100 $9 960 198 $1 489 880 57 615 22 $69 107
3. Late ANC + 14 weeks 66 5 7% 3100 $11 345 338 $1 385 140 57 610 4 $316 654
5. Late ANC + 9 months 66 5 6% 3100 $11 372 961 – 57 612 – Dom
4. Late ANC + 6 months 67 5 6% 3100 $11 397 314 – 57 612 – Dom
6. Late ANC + 6 months +
9 months
66 5 7% 3100 $12 799 222 – 57 611 – Dom
7. Late ANC + every
3 monthsc
66 5 8% 3100 $14 168 275 $2 822 937 57 608 3 $1 087 274
ANC, antenatal care; PP, postpartum; DALY, disability-adjusted life-year; Dom, dominated (more costly and less effective than dominating scenar-
io).
a
Late ANC is between 36 to 39 weeks of gestation;
b
Testing offered in late ANC, or at delivery if not performed at late ANC, or at six week
MCH visit if not performed at delivery or late ANC;
c
Approximately every three months PP includes retesting at six weeks, 14 weeks, six months
and nine months PP;
d
% infections averted is calculated by dividing total infections averted by the total number of infant infections that occur
under Scenario 1 (no retesting);
e
ICER, incremental cost-effectiveness ratio, calculated as incremental costs (in 2017 US$) divided by DALYs
averted compared with the next least-costly scenario with dominated and weakly dominated scenarios removed.
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Optimizing MCH attendance and HIV care cascade parame-
ters had little impact on these results. Antibody-based testing
has low sensitivity during acute infection, when transmission
risk is highest, making incident infections more difficult to
detect. Our results thus suggest that achieving EMTCT will
require additional interventions for prevention, such as PrEP,
partner testing or diagnostics that facilitate earlier detection
of incident infections.
In Colombia and Ukraine, where postnatal risk of maternal
HIV acquisition is low, as is subsequent MTCT risk due to low
rates of breastfeeding, the impact of postpartum retesting is
similar to antenatal retesting. Decisions on implementation of
maternal retesting will depend on national priorities (such as
EMTCT), programmatic goals and targets, and available
resources, and countries with low HIV prevalence may con-
sider retesting women at higher risk of HIV, including key
populations (e.g. women who inject drugs, female sex workers)
and those in serodiscordant relationships. Risk-based screen-
ing tools, such as the one developed for pregnant and post-
partum Kenyan women [39], may help identify such women
during pregnancy or postpartum in both high and low preva-
lence settings.
Although our findings suggest maternal retesting is cost-ef-
fective in countries with high maternal HIV prevalence, there
are several factors that need to be considered when imple-
menting this strategy. First, country guidelines need to provide
clear criteria on retesting eligibility and timing [10]. Countries
should consider provider capacity to offer retesting given
their workload and ensure monitoring and evaluation activities
both document testing history and measure impacts of retest-
ing. Providers who offer testing will need training to deliver
post-test counselling messages that address HIV risk during
pregnancy and breastfeeding and the need for future retest-
ing, in addition to reinforcing HIV prevention messages.
Emphasizing the importance of maternal retesting to prevent
MTCT may also help providers prioritize retesting during busy
ANC or postnatal care/infant immunization visits, including
conveying elevated risks of HIV acquisition during pregnancy
and breastfeeding and subsequent MTCT. Finally, test kit pro-
curement and supply-chain management must be optimized to
ensure test kit availability at facilities and that maternal
retesting does not hinder other HIV testing efforts.
We found additional postpartum retesting incurs high costs
per DALY averted, thus countries adopting this approach will
need innovative and differentiated retesting models to opti-
mize resource use [2]. Because HIV test coverage at first
ANC visit is high in most countries, alternative delivery
approaches to retesting may increase coverage among women
who only attend one ANC visit, deliver at home, and/or do
not return for MCH visits for postnatal care/infant immuniza-
tions. The WHO recommends self-testing as an additional
testing approach [40]; however, to date few programmes have
introduced self-tests for maternal retesting. While self-tests
are unlikely to replace clinic-based rapid tests, they may play a
complementary role in PMTCT programmes to increase
access and acceptability of retesting and should be evaluated
Figure 1. Efficiency frontier. presenting the incremental disability-adjusted life years (DALYs) averted and costs (in 2017 USD) for six retest-
ing scenarios relative to Scenario 1 (no retesting) in (a) Kenya, (b) South Africa, (c) Colombia, (d) Ukraine. The solid line indicates scenarios
that are not dominated by other scenarios, where “dominated” indicates a scenario is more costly and less effective. The text indicates
incremental cost-effectiveness ratios for the non-dominated scenarios compared to the next least-costly scenario connected by a solid line.
Scenario 1: no retesting; Scenario 2: retesting in late ANC/delivery/6 weeks postpartum; Scenario 3: scenario 2 plus retesting at 14 weeks
postpartum; Scenario 4: scenario 2 plus retesting at six months postpartum; Scenario 5: scenario 2 plus retesting at nine months postpartum;
Scenario 6: scenario 2 plus retesting at both six and nine months postpartum; Scenario 7: scenario 2 plus retesting every three months post-
partum.
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for maternal retesting in future studies. In the context of the
COVID-19 response, due to declining and delayed facility vis-
its in many settings, HIV self-tests are increasingly being con-
sidered as a way to provide maternal catch-up testing and
retesting for programmes and should be considered and eval-
uated.
Our analysis has several strengths. We model delivery of
HIV retesting at routine ANC and MCH visits, mitigating the
costs incurred by retesting. A similar strategy could be
adopted for HIV testing in conjunction with routine paediatric
vaccination past the MCH visits included in our model. We
assessed the impact of additional tests during the postnatal
period, which is included in comparatively fewer national
guidelines than retesting during late pregnancy/delivery [10].
Furthermore, we included countries with different HIV burden
and geographic locations. While countries modelled are cur-
rently not implementing PrEP for pregnant and postpartum
women at the national level, we assessed the impact of future
PrEP scale-up on retesting strategies in sensitivity analyses.
We also modelled reductions in maternal HIV incidence that
could result from other HIV prevention interventions that
may benefit pregnant/lactating women (i.e. condom use, risk
reduction, partner HIV testing) [40]. Our conclusions were
robust to varying assumptions about HIV prevalence, inci-
dence and PrEP scale-up.
Our analysis also has several limitations. Some parameter
values were assumed due to lack of empiric data; however,
our estimates of MTCT rates were consistent with published
estimates. While we modelled paediatric ART costs through
20 years, we modelled maternal ART costs only through
Figure 2. One-way parameter uncertainty analyses in (a) Kenya and (b) South Africa under retesting Scenario 2 (retesting in late ANC/deliv-
ery/six weeks postpartum). Models included 20% relative increases and decreases in individual parameters, bounded by 0 and 1 for proba-
bilities. ANC, antenatal care visit; PP, postpartum; ART, antiretroviral therapy; NBF, not breastfeeding; ARV, antiretroviral prophylaxis; HIV+,
HIV positive; ICER: incremental cost-effectiveness ratio, calculated as incremental costs (in 2017 US$) per disability-adjusted life year
averted. HIV incidence refers to both incidence between onset of pregnancy and first antenatal care (ANC) visit, and incidence between first
ANC and delivery, with both parameters varied by 20% for this analysis. HIV test coverage is the product of test acceptance and test kit
being in-stock, with the composite parameter (test coverage) varied by 20% for this analysis.
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Figure 3. Scenario implementation analysis of maternal HIV retesting. (a) Decreasing HIV prevalence in Kenya and South Africa, (b) Decreas-
ing HIV prevalence in Colombia and Ukraine, (c) Decreasing HIV incidence in Kenya and South Africa, (d) Decreasing HIV incidence in
Colombia and Ukraine, (e) Increasing PrEP use in Kenya and South Africa, (f) Increasing PrEP use in Colombia and Ukraine, (g) Decreasing
HIV prevalence and incidence, increasing PrEP use in Kenya and South Africa, (h) Decreasing HIV prevalence and incidence, increasing PrEP
use in Colombia and Ukraine. ANC, antenatal care; PrEP, pre-exposure prophylaxis; ICER, incremental cost-effectiveness ratio; DALY,
Disability-adjusted life year, Maternal HIV retesting Scenarios 2 (retesting in late ANC/delivery/six weeks postpartum) and 3 (retesting in late
ANC/delivery/six weeks postpartum and at six months postpartum) modelled. ICERs are calculated with respect to Scenario 1 (no retesting).
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12 months postpartum, as maternal outcomes were not the
focus of our model and we assume MTCT ceases after
12 months. We did not model any changes in infant ARV and
paediatric ART costs over this period, but our results were
robust to changes in costs in sensitivity analyses. HIV diagno-
sis and linkage to care improves maternal health outcomes
and may also prevent horizontal transmissions, neither of
which are not captured by our model. While our intent was to
model retesting in late pregnancy, tests in late ANC capture
both incident maternal infections and established infections
not detected at first ANC due to late presentation (after the
gestational age of first ANC modelled) or absence of testing
at first ANC. Furthermore, our model only allows for testing
at two antenatal time points, with parameterization corre-
sponding to re-testing in the third trimester in South Africa
and Kenya, and in the second trimester in Colombia and
Ukraine. As our model did not stratify by demographic or HIV
risk factors, our results may not represent the impact of
maternal retesting in concentrated epidemics within a country,
nor of retesting prioritized for key populations. Our choice of
countries was constrained by data availability and may not be
generalizable to other settings where key parameters differ
substantially from those modelled. We did not explicitly model
time since maternal ART initiation and therefore may not have
captured more complex temporal patterns in maternal ART
use. Our model assumed all HIV-infected infants were equally
likely to receive ART regardless of whether their mother’s
HIV-positive status was known or unknown. As early diagnosis
and treatment will avert DALYs even if transmission is not
prevented, our results are conservative in this regard. Our
results are presented as point estimates without accompany-
ing uncertainty. As several of our model parameters were
based on expert elicitation or assumptions, and we expect
many are correlated, we felt valid parameterization of a formal
probabilistic sensitivity analysis was out of reach. Finally, the
cost-effectiveness thresholds used in this analysis are approxi-
mate and may not accurately reflect country-specific willing-
ness-to-pay under budget constraints. Affordability constraints
may prevent some countries from implementing interventions
below these thresholds. Alternatively, in efforts to achieve
EMTCT, programmes may consider incurring high costs to
implement retesting strategies above the cost-effectiveness
thresholds used in this analysis.
5 | CONCLUSIONS
We found retesting women in late ANC followed by catch-up
testing though six weeks postpartum is a cost-effective approach
to PMTCT in Kenya and South Africa and should be implemented
by PMTCT programmes. Universal maternal retesting was not
cost-effective in Colombia and Ukraine; these counties may con-
sider retesting if resources are available as retesting does con-
tribute to EMTCT efforts, which would align with their current
national retesting guidance. Additional empiric data on imple-
menting maternal retesting guidelines is needed to refine model
inputs, to evaluate retesting strategies for key populations at
high HIV risk, and to revise retesting guidelines as incidence
declines in high-burden countries.
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Figure S1. Scenario implementation analysis of maternal HIV
retesting on number of infant HIV infections averted. (a)
Decreasing HIV prevalence in Kenya and South Africa, (b)
Decreasing HIV prevalence in Colombia and Ukraine, (c)
Decreasing HIV incidence in Kenya and South Africa, (d)
Decreasing HIV incidence in Colombia and Ukraine, (e)
Increasing PrEP use in Kenya and South Africa, (f) Increasing
PrEP use in Colombia and Ukraine, (g) Decreasing HIV preva-
lence and incidence, increasing PrEP use in Kenya and South
Africa, (h) Decreasing HIV prevalence and incidence, increas-
ing PrEP use in Colombia and Ukraine. ANC, antenatal care;
PrEP, pre-exposure prophylaxis; Maternal HIV retesting Sce-
narios 2 (retesting in late ANC/delivery/six weeks postpartum)
and 3 (retesting in late ANC/delivery/six weeks postpartum
and at 6 months postpartum) modelled.
Appendix S1. Model hyperlink: https://github.com/dallenrobe
rts/Maternal-testing
Appendix S2. Model equations.
Appendix S3. Model parameters
Appendix S4. Comparison of model vs published estiamtes of
maternal to child transmission
Appendix S5. Microcosting methods
Appendix S6. Infections averted under optimized MCH atten-
dance and HIV care cascade
Meisner J et al. Journal of the International AIDS Society 2021, 24:e25686
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25686/full | https://doi.org/10.1002/jia2.25686
12
